There are certain devastating diseases that have been affecting the world in the present scenario. The treatment for diseases like Alzheimer, type 2 diabetes, lupus and rheumatoid arthritis have become a great task for the National Institutes of Health and undertaking ambitious tie ups with private companies to deal with the relevant treatments.
The pilot projects have made an announcement recently that they will be getting involved in the sharing including the scientists as well as the datas, tissue specimens and the samples of blood etc amongst the federal government, research foundations, non profit groups and also the 10 rival companies.
The investments from the first projects are expected to be more than $230 million, lasting upto 3-5 years. The indrustries participating in this include GlaxoSmithKline, J&J etc. also some of the biotech companies. The main aim of the collaboration is to change the fundamentals of the biomedical research. Accelerating Medicines Partnership (AMP), is an iniative method which intends to bring the scientists from industry and government to take the world wide possibilities and come out with best possible outcomes for treatment. Francis S. Collins, Director of NIH, said that the researchers are working hard in growing up the field that have found failures in the past. He also added that the scientists are trying to pick up the right targets for the drug development by taking account of the miney and the time.
The foundation of data analysis was done by analysing the human genome. As a part of this there were great changes to the specific research areas:
- Process, store and and analysis of high resolution images.
Some of the breakthrough in the treatments occur for patients also every year the researchers abandons 90-99% of drugs. The most painful case is when the research fails as the drugs reaches phase 2 and phase 3 trials on clinical aspects with patients. The scientists are making innovative and best methods in this field that can save money as well as time can be saved and this is made possible by mind sharing and data sharing.
The collaboration is a necessity part and its not an option. Since its very expensive it is difficult to develop or utilize the technologies by oneself. So the research organizations has to come forward and present the next generation drugs to the needy.